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Abstract 
Retinitis Pigmentosa GTPase Regulator (RPGR) gene sequence variants account for 
the vast majority of X-linked Retinitis Pigmentosa (RP), which is one of the most 
severe forms of RP. Symptoms of nyctalopia typically begin in childhood, with 
increasing loss of peripheral visual field during teenage years, and progressive 
central visual loss during the second to fourth decade of life. There is however 
marked intra- and interfamilial phenotypic heterogeneity both in affected males and 
carrier females. There is now a far greater understanding of the range of phenotypes 
associated with variants in this gene; including rod-cone dystrophy, cone-rod 
dystrophy, cone dystrophy, macular dystrophy and non-ocular phenotypes. There 
are also increasingly established genotype-phenotype associations and structure-
function correlations. RPGR is involved in ciliary function, with ciliary dysfunction 
now recognized as the mechanism underlying a large proportion of inherited retinal 
disease. There has been significant progress in both identifying naturally occurring 
animal models and developing novel models to define the underlying disease 
mechanisms and to test gene replacement therapy, in addition to advances in 
human retinal imaging, culminating in completed and planned clinical trials. These 
significant developments will be discussed.  
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Introduction  
Hereditary retinal disorders are now the leading cause of blindness in working age 
adults in England and Wales, and the second commonest in childhood [1]. Retinitis 
pigmentosa (RP), a group of genetically and phenotypically diverse disorders, affects 
~ 1:3000 to 1:4000 and is inherited as an autosomal dominant, recessive or X-linked 
(XL) trait; which are estimated to account for 30-40%, 45-60% and 5-15% of cases 
respectively [2-6]. X-linked retinitis pigmentosa (XLRP) is particularly severe, with 
early-onset in childhood, progressing to severe visual impairment by the third to 
fourth decade. Retinitis Pigmentosa GTPase Regulator (RPGR) gene sequence 
variants account for 70-80% of XLRP [7-9], RP2 variants for a further 5-20% [8-12], 
and a third gene, OFD1 has been identified as a rare cause of XLRP [13]. This review 
focuses on the molecular genetics and phenotypic features of RPGR retinopathy, 
animal models and therapeutic options.   
 
Molecular Genetics of RPGR  
RPGR was first identified as a cause of XLRP in 1996, composed of 19 exons and 
encoding a 90kDa protein product, with exons 2-11 coding for a structure similar to 
regulator of chromosome condensation 1 (RCC1) at the N-terminus [7 14]. RCC1 is a 
well-characterised protein that functions as a guanine nucleotide exchange factor for 
Ran (a Ras-related nuclear protein) and is thought to play an important role in 
nucleo-cytoplasmic transport and regulation of cell division [15 16]. Further analysis 
identified a transcript with a novel 3’ terminal exon known as exon open reading 
frame 15 (ORF15) that includes exon 15 and a portion of intron 15 [17]. Only 10-20% 
of patients with XLRP harboured disease-causing sequence variants in RPGR prior to 
RPGR-associated Retinopathy 4 
the discovery of ORF15. The ORF15 exon has an unusual repetitive sequence 
encoding 567 amino acids rich in glycine and glutamic acid residues that is a 
“mutational hotspot”, harbouring approximately 60% of all XLRP variants, thus 
underlying the majority of XLRP [17]. To date, over 300 variants have been identified 
in RPGR [18 19]. 
 There are multiple RPGR isoforms arising from alternative splicing [20-24] or 
post-translational modification [25].  These isoforms are expressed in different 
amounts in different tissues (lung, kidney, retina, brain, testis); suggesting tissue-
specific splicing with tissue-specific functions.  The two major RPGR isoforms are the 
constitutive RPGR exon 1-19 and RPGR ORF15 [16], with RPGR ORF15 representing 
the isoform that is most highly expressed in retina [17]. To the best of our 
knowledge, all disease-causing variants are found in exons present in isoform RPGR 
ORF15, with only one in exons 15-19 [26], supporting the importance of the RPGR 
ORF15 isoform in the retina.  
 
RPGR Interacting Proteins and Function 
RPGR comprises an RCC1-like domain at its N-terminus, and the predicted function 
of the unusual C-terminal ORF15 protein sequence is not known. As illustrated in 
Figure 1, RPGR is localised predominantly to the photoreceptor connecting cilium 
[24], which is the equivalent of the transition zone of motile and primary cilia. An 
RPGR protein interaction network has been established, either through genetic 
studies identifying disease genes with overlapping symptoms, or through targeted 
functional studies, or a combination of both [16 27-29]. Some of the principal 
interacting proteins will be alluded to herein. Retinitis pigmentosa GTPase regulator-
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interacting protein (RPGRIP1) localizes to the connecting cilia and is thought to hold 
RPGR in this locale [28]. Similarly, retinitis pigmentosa GTPase regulator-interacting 
protein-1 like protein (RPGRIPL1), delta subunit of rod cyclic GMP phosphodiesterase 
(PDEδ), structural maintenance of chromosomes 1 and 3 (SMC1/3), GTPase Rab8A, 
nephrocystin-5, and whirlin also have been shown to interact with RPGR [29-35].  
Although the function of RPGR is not fully understood, information from 
biochemical studies and the phenotypes in patients and animal models, strongly 
suggests that it plays a role in the transport of phototransduction components and 
other outer segment proteins across the connecting cilium. Biochemical studies have 
shown that RPGR-ORF15 localises to the connecting cilium of the photoreceptor and 
binds to the basal body and the axoneme [30 36]. Involvement of RPGR-ORF15 in 
transport is suggested in immunoprecipitation experiments that show that RPGR 
interacts with γ-tubulin, subunits of Kinesin II and dynein microtubule motor protein 
complexes, and intraflagellar transport polypeptide 88 (IFT88) [30]. However, these 
interactions do not exclude that RPGR-ORF15 may be involved as cargo in these 
processes, rather than as an active component.  
The most prominent and consistent evidence for a role in ciliary transport is 
provided by various post-mortem studies that have utilised immunohistochemical 
techniques to demonstrate opsin mislocalisation within the photoreceptor structure 
in human, canine and mice models of RPGR-deficient carriers and affected subjects 
[37-41]. Opsin molecules are G-protein coupled receptors integral to visual 
phototransduction. These are assembled within the organelles of the photoreceptor 
inner segment and systematically transported via the connecting cilium to their final 
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destination in the outer segment where they are contained within the disc 
membranes [42].  
Cone and rod opsin mislocalisation to photoreceptor inner segments, 
perinuclear regions and synaptic terminals has been shown in human and canine 
subjects [37 40 41]. Cone but not rod opsin mislocalisation to similar regions have 
also been found in mice models, together with a reduction in rhodopsin levels within 
the outer segments [38 39].  
The structure of the connecting cilium is not compromised in RPGR-deficient 
photoreceptors, and the presence of correctly localised opsins and relatively well 
preserved vision in the early stages of disease indicate that RPGR plays a facilitative 
rather than an essential role in the transport process [39]. A role in docking and 
selection of cargo at the basal body has been suggested [30 36]. 
How opsin mislocalisation affects photoreceptor viability to cause retinal 
degeneration remains unclear. A mechanism whereby ectopic G-protein activity is 
stimulated by mislocalised opsin molecules leading to photoreceptor apoptosis has 
been postulated but retinal degeneration has also been shown to occur despite G-
protein inactivation [43 44]. However, a causal link between opsin mislocalisation 
and subsequent retinal degeneration has not been proven and it is possible that 
photoreceptor viability is affected by other molecular pathways unrelated to opsin 
mislocalisation, which in itself may simply be a marker of ensuing retinal 
degeneration.  
The amino acid sequence of RPGR provides a clue to its function [14]. The 
main recognisable feature is its RCC1 homology domain that suggests a function as a 
guanine nucleotide exchange factor for Ran (a Ras-related nuclear protein) and 
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catalysis of RanGTP [15]. RanGTP serves as an energy source for molecular motors 
that move cargo through the nuclear pore complex. The resultant high local 
concentration of RanGTP in the connecting cilium as generated by RPGR could 
enable a putative RanGTP-dependent process that drives unidirectional movement 
of opsins across the connecting cilium to the outer segment [39 45]. 
 
RPGR Animal Models  
Two naturally occurring RPGR ORF15 mutations in the Siberian husky canine breed 
result in distinct phenotypes. A 5-nucleotide deletion in RPGR ORF15 (del1028-1032) 
gives rise to a premature stop codon and truncation of 230 residues, resulting in X-
linked Progressive Retinal Atrophy 1 (XLPRA1) secondary to loss of RPGR function 
[46]. This phenotype is characterised by gradual photoreceptor degeneration that is 
post-developmental in onset, affecting rods more than cones, in keeping with 
human RP, albeit with slower progression. Optical coherence tomography (OCT) 
demonstrates normal outer nuclear layer (ONL) thickness up to 28 weeks of age, 
while at older ages (from 56 weeks) ONL thickness starts to decline in the inferior 
retina while initially remaining preserved at the visual streak [47]. The second more 
severe phenotype, XLPRA2, is caused by a 2-nucleotide deletion in ORF15 (del1084-
1085), downstream to the first, resulting in frameshift and the inclusion of 34 basic 
amino acids with truncation of 161 residues [46]. OCT demonstrates a generalised 
decline in ONL thickness that is worse at the cone-rich central visual streak than the 
periphery [47].  
 It has been proposed that the early onset of disease in XLPRA2 from around 
5 weeks, with rapid progression affecting both rods and cones, may be caused by a 
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toxic gain of function from an accumulation of abnormal protein product in the 
endoplasmic reticulum [40 46]. However, the treatment effect shown after adeno-
associated viral (AAV) vector mediated RPGR gene transfer in these animals [47] 
argues against a gain of function mechanism. The finding that two distinct 
phenotypic expressions of XLPRA are related to the exact nature and position of the 
ORF15 mutations [46] appears to be confirmed by genotype-phenotype correlations 
in patients as discussed below [9].  
Three mouse models of RPGR deficiency exist. In the first, generated by the 
deletion of RPGR exons 4-6 [39], cone opsin mislocalisation to inner segments, 
nuclear and synaptic regions was seen and rhodopsin levels were reduced in rods 
when examined 20 days postnatally. Retinal structure however was comparable to 
wild-type and electroretinogram (ERG) function was within normal limits despite a 
lack of RPGR. However, by 6 months, photoreceptor cell loss was apparent [39]. This 
model demonstrates a slow retinal degeneration, not dissimilar to XLPRA1, and 
therefore does not emulate the severe degeneration in humans [46]. One of the 
major shortfalls of murine models to recapitulate human disease is a predominance 
of rods over cones. In addition, there may not have been a total absence of RPGR 
protein product as residual RPGR ORF15 isoform was reported to be present in this 
model [30]. However, two further mouse models, one a naturally occurring 32 base 
pair duplication in ORF15 [38], the other an engineered deletion of exon 1 [48], show 
very similar phenotypes to the original knock-out mice. As these models do not 
appear to have residual RPGR protein, it is unlikely that the putative presence of 
remaining protein causes the relatively slow rate of degeneration in the murine 
retina. 
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RPGR Clinical Phenotypes 
Disease-causing sequence variants have been identified in RPGR in association with a 
range of phenotypes including rod-cone dystrophy or retinitis pigmentosa (RP), cone 
dystrophy (COD), cone-rod dystrophy (CORD), macular atrophy, and rarely 
syndromic XLRP. RP and CORD are the commonest and best described conditions, so 
genotype-phenotype correlations will be discussed. The vast majority of retinal 
disease-causing mutations are loss-of-function alleles, with the majority of these 
being protein truncations in ORF15. 
 
RPGR Retinitis Pigmentosa (Rod-Cone Dystrophy)  
XLRP is one of the most severe forms of RP, with nyctalopia in most affected males 
before ten years of age and progression to legal blindness by the third to fourth 
decade [49]. Myopia, retinal and electrophysiological abnormalities are often 
present from childhood [49 50]. Most carrier females are asymptomatic or mildly 
affected, with a minority of females as severely affected as males [50-52]. A 
significant proportion of carrier females can be identified on the basis of a tapetal 
reflex seen clinically and/or with fundus autofluorescence (FAF) imaging, and/or 
generalised retinal dysfunction on electrophysiological testing. 
            A parafoveal hyperautofluorescent ring is present in some male patients on 
FAF imaging [53-55]. There is good correlation between ring radius and pattern ERG 
P50 amplitude (measure of macular function), indicating greater preservation of 
function with larger rings; this ring constricts over time and thereby may be a 
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measure of rate of progression both in the clinic and as an end-point for clinical trials 
[53-55].  
            An OCT-based ‘transition zone’ model has been described with progression 
from an intact foveal centre to diseased periphery, evidenced first by outer segment 
shortening, followed by decreased ONL thickness and further outer segment loss, 
preceding inner segment ellipsoid zone (EZ) band disappearance [56]. Annual width 
decrease of the EZ band was estimated at 248 μm/year in a group of 28 XLRP 
patients [57]. Functional correlates have been probed, using static perimetry, in 40 
patients with RPGR XLRP, with demonstration of greatest rate of decline in retinal 
sensitivity located at the edges of EZ band disappearance [58].  
Sharon et al [9] screened RP2 and RPGR in 187 unrelated male patients and 
their affected relatives, and identified disease-causing variants in 16 and 156 
patients respectively, with 71% (111/156) of RPGR mutations in ORF15. Age-
matched patients with RPGR ORF15 sequence variants had milder disease compared 
with patients with RPGR exon 1-14 variants, including larger intact visual fields and 
30Hz ERG amplitudes, suggesting that the truncated mutant protein is able to 
perform some function, for example through the intact RCC1-like domain, or that a 
role exists for constitutive RPGR within ORF15 mutant photoreceptor cells. It was 
also proposed that for patients harbouring ORF15 variants, disease severity varied 
according to the predicted length of the encoded abnormal amino acid sequence; 
with relatively better retinal function associated with longer wild-type ORF15 amino 
acid sequences secondary to more downstream variants [9]. Moreover, mutations in 
the first 14 exons that affect both constitutive RPGR and the RPGR ORF15 isoforms 
lead to the most severe disease. 
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Fahim et al [59] studied 98 affected males with 44 different RPGR mutations. 
Patients were grouped into 3 categories of disease severity based on ERG and 
Humphrey visual field findings. In keeping with Sharon et al [9], patients with exon 1-
14 variants (often predicted null alleles) had more severe disease than patients with 
ORF15 variants (predicted potentially translatable transcripts); with ORF15 disease 
being associated with far greater variability in disease severity. 
 Several studies have identified that ORF15 variants causing RP are far more 
frequently located towards the 5’ end, whereas variants located towards the 3’ end 
of ORF15 more often result in COD/CORD [60-64]. However, there remains 
significant intra- and inter-familial variability with examples of both RP and CORD 
within the same families despite the same underlying sequence variant in RPGR [61 
65 66], suggesting that genetic and/or environmental modifiers are also influencing 
phenotype.  
 
RPGR Cone and Cone-Rod Dystrophy 
Disease-causing sequence variants in RPGR are the commonest cause of XLCOD and 
XLCORD [62]. Multiple studies have reported detailed phenotypic findings in both 
affected males and carrier females [62-64 67-70]. Onset of central visual loss in 
affected males ranges from the second to the fourth decade, are often myopic, with 
significant inter- and intra-familial variability both in terms of onset, rate of 
progression, and rod involvement. This phenotypic heterogeneity is the hallmark of 
inherited retinal disease and suggests an important role for genetic modifiers and 
environmental factors. 
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In keeping with X-linked inheritance, most carrier females are asymptomatic 
or mildly affected, with a minority of females as severely affected as males [64]. 
Variability between and within families is believed to be primarily due to varying 
degrees of skewed X-inactivation, although other genetic modifiers have been 
proposed [62 64 67-71]. 
              Parafoveal hyperautofluorescent rings are present in some RPGR COD and 
CORD male patients on FAF imaging and can progressively increase in size over time. 
In contrast to RP rings, the size of CORD rings is inversely related to pattern ERG P50 
amplitude, indicating worse macular cone function with large rings [53 64 72]. 
 To date all reported patients with COD/CORD harbour variants in ORF15 – 
with ORF15 variants causing COD/CORD more frequently located towards the 3’ end 
of ORF15 compared to those causing RP [60-64].  
 
RPGR Associated Syndromic Ciliopathy 
Cilia defects cause a wide range of genetic conditions, collectively called ciliopathies.  
It is now well established that many important retinal proteins have a role in cilia 
function and retinal dystrophy represents a common phenotype in the clinical 
spectrum of disease [73]. Further evidence for RPGR having an important role in cilia 
function came from genetic studies where sensorineural hearing loss, bronchiectasis 
and respiratory tract infections were associated with XLRP caused by an RPGR 
mutation [74]. Additional families have been reported with variable penetrance of 
these phenotypes, confirming further cases of syndromic disease [50 75 76]. 
Interestingly, mutations causing syndromic XLRP, to date, are restricted to exons 1-
14, suggesting mutations in ORF15 may not be a cause of extra-ocular phenotypes.   
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Therapeutic Options  
Docosahexaenoic acid (DHA) and Vitamin A  
Lipids make up ~ 25% of photoreceptors’ dry weight, with photoreceptor outer 
segment membranes containing equal amounts of proteins and lipids, with 80% or 
more of lipid composition arising from phospholipids [77]. In human rod outer 
segments, 20-30% of fatty acids within phospholipids are made up of 
docosahexaenoic acid (DHA or 22:6ω3) [77]; thereby suggesting an important 
biochemical role in photoreceptors. DHA and vitamin A are both essential 
components of the visual cycle. Interphotoreceptor retinoid-binding protein (IRBP) 
can bind either palmitate or DHA resulting in an alteration in affinity for vitamin A 
isomers [78].  IRBP when located near the retinal pigment epithelium (RPE) 
predominantly binds palmitate, creating high affinity for 11-cis retinal, which is 
thereby bound and transported to rod outer segments. High levels of DHA in rod 
outer segments lead to a swap in IRBP fatty acid binding, with subsequent release of 
11-cis retinal to the outer segments where it forms rhodopsin. Following 
phototransduction, all-trans retinol in the outer segment is bound to IRBP and 
brought back to the RPE, where DHA is swapped with palmitate thereby resulting in 
a release of all-trans retinol for 11-cis retinal [78].  
It has therefore been suggested that a lack of DHA, secondary to outer retinal 
degeneration, may hinder the release of 11-cis-retinal, thus giving rise to the 
hypothesis that DHA levels around photoreceptor outer segments can be increased 
(in order to facilitate release of 11-cis retinal) with DHA supplements or alternatively 
by increasing retinal levels of 11-cis retinal with vitamin A supplementation [79]. 
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A Cochrane review [80] assessed 3 randomised controlled trials on the 
effectiveness of vitamin A or DHA in RP, including XLRP [81-83]. No clear evidence of 
benefit with either vitamin A or DHA supplementation was identified on the basis of 
visual field or ERG parameters. As a result, high dose vitamin A supplements are not 
routinely recommended to patients. It is generally accepted that eating a healthy 
and balanced diet, one that is rich in green vegetables and oily fish that will provide 
good amounts of lutein and omega-3 is instead likely to be of value.  
 
Neuroprotection 
There is evidence from animal studies that ciliary neurotrophic factor (CNTF) 
delivered either with intravitreal injection of CNTF protein or gene therapy mediated 
with adeno-associated viral (AAV) vectors exerts a neuroprotective effect on rods, 
with slowing or halting of retinal degeneration [84]. Recombinant human CNTF has 
been shown to stimulate cone outer segment regeneration in a rat model of 
advanced retinal degeneration where rods have already degenerated [85]. In 
addition, sustained CNTF delivery via implanted devices was shown to preserve cone 
ERG response and function in the same rat model. [85] 
 A phase II/III trial has been undertaken of intravitreal implants of 
encapsulated human retinal pigment epithelium cells engineered to continuously 
secrete CNTF protein in patients with early (n=68) and late-stage (n=65) RP [86]. 
Patients were randomly assigned to receive a high- or low-dose implant in 1 eye and 
sham surgery in the fellow eye. Primary endpoints were change in best-corrected 
visual acuity at 12 months for late-stage RP and change in visual field sensitivity at 12 
months for early RP.  Neither study showed therapeutic benefit – with some patients 
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experiencing loss of retinal sensitivity that was reversible on removal of the implant. 
However, a pilot study utilising adaptive optics imaging to investigate in vivo cone 
structure in 3 patients with CNTF implants over a 24 month period found that cone 
density remained stable in eyes with a CNTF implant whereas there was continued 
cone loss in untreated fellow eyes, suggesting that more sensitive metrics are 
needed as primary outcome measures in slowly progressive diseases such as RP [87]. 
 
Gene Therapy  
Successful photoreceptor rescue with RPGR ORF15 transgenes has been 
demonstrated in animal models. Hong et al [88] generated a transgenic mouse 
model that carried mouse RPGR ORF15 variant on an RPGR null background. The 
selected RPGR ORF15 variant had a 654 base pair deletion within the repetitive 
purine rich region. Protein expression levels 20% that of wild-type was observed 
with localisation to the connecting cilia, sufficient for structural and functional 
rescue of photoreceptors. Another more recent study in RPGR null mice has been 
carried out via subretinally injected AAV vector mediated delivery of two shortened 
human RPGR ORF15 transgenes [89]. The repetitive purine rich region was 
shortened by 378 base pairs for the first transgene and 942 base pairs for the second 
transgene. Protein expression followed with both versions of transgene. Appropriate 
subcellular localisation to the connecting cilia and comparable immunofluorescence 
signal intensity to wild type was seen with the longer protein, with structural and 
functional rescue of photoreceptors. A much weaker immunofluorescence signal 
was however obtained with the shorter gene. A greater efficacy is anticipated with 
the moderately shortened yet functional version of human RPGR ORF15 transgene 
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compared with the wild-type gene, as the long and repetitive purine rich region 
present in full length RPGR ORF15 is less stable and this may affect the efficacy of 
gene transfer to photoreceptor cell nuclei. The improved efficacy would be 
favourable for future human gene therapy trials.  
 XLPRA1 and XLPRA2 canine models have been successfully rescued with 
subretinal injection of AAV delivering human RPGR ORF15 [47]. Post-treatment 
monitoring with in vivo OCT imaging demonstrated a preserved ONL and greater 
inner segment ellipsoid layer integrity in the retina exposed to vector compared to 
adjacent un-injected retina, in both XLPRA1 and XLPRA2. These findings were 
confirmed with histopathology, whereby prevention or reversal of opsin 
mislocalisation was observed only in the subretinally treated areas. The 
development of retinal degeneration was prevented with early treatment in XLPRA1, 
whereas in XLPRA2, due to the earlier onset of this phenotype, intervention during 
disease progression allowed morphological restoration of remaining photoreceptors 
[47]. 
 
Conclusions  
The successful rescue in the aforementioned animal models and the safety and 
efficacy demonstrated in previous gene therapy trials for Leber Congenital 
Amaurosis associated with RPE65 deficiency [90-92] have paved the way for several 
groups around the world to prepare for Phase I/II gene replacement trials in the near 
future. However, there is a limiting lack of robust natural history data in large 
genetically proven groups of patients with XLRP and XLCORD due to RPGR. These 
data are needed in order to design clinical trials of planned gene replacement 
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therapy. As observed with the CNTF clinical trial, novel outcome metrics are needed 
in such relatively slowly progressive disease to sensitively detect change in a timely 
and robust fashion, which may include quantitative retinal imaging with OCT and 
adaptive optics scanning light ophthalmoscopy. The significant progress made in 
understanding disease-mechanisms and treatment modalities are exciting and make 
the aim of future targeted treatments a realistic possibility [93].  
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